Famar

In October 2024, MidEuropa completed the acquisition of a controlling stake in FAMAR, a well-established pharmaceutical contract development and manufacturing organisation (CDMO), from ECM Partners and Metric Capital Partners. MidEuropa invested alongside the management team and current shareholders, who retained a minority stake.

FAMAR is a trusted partner to a diversified blue-chip client base of pharmaceutical companies operating in more than 80 international markets. The Company provides a full-service offering across the CDMO value-chain, with broad capabilities across multiple dosage forms including sterile, solids, semi-solids, and R&D services. FAMAR employs over 1,800 people working across a network of six manufacturing sites located across southern Europe with two complementary R&D centres

Partnership highlights

• Operating in the resilient and structurally growing pharma CDMO market
• Full suite of pharma products with key capabilities across multiple dosage forms including steriles, as well as R&D services
• Diversified and growing customer base of c.100 blue-chip pharma and consumer health companies
• CDMO platform operating into a highly fragmented space with significant potential for capabilities expansion in key formulations and R&D

Value creation

• Organic Growth
• Greenfield Rollout
• Acquisitive Growth
• Operational Excellence